Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, 225001, People's Republic of China.
Department of Obstetrics and Gynecology, College of Clinical Medicine, Yangzhou University, Yangzhou, 225001, People's Republic of China.
Anal Bioanal Chem. 2022 Nov;414(26):7659-7673. doi: 10.1007/s00216-022-04296-w. Epub 2022 Sep 2.
In this work, a microfluidic chip using Au@SiO array-based highly active SERS substrates was developed for quantitative detection of squamous cell carcinoma antigen (SCCA) and carcinoembryonic antigen (CEA) associated with cervical cancer. The chip consisted of six functional units with pump-free design, enabling parallel detection of multiple samples in an automatic manner without external pumps and improving the portability. Ag nanocubes (AgNCs) were labeled with Raman reporters and coupled with antibodies (labeling) to prepare SERS tags, while the Au nanoparticle-modified SiO microsphere (Au@SiO) array was conjugated with antibodies (coating) to generate the highly SERS-active capturing substrate. In the presence of target biomarkers, they were captured by SERS tags and capturing substrate, resulting in the formation of "sandwich" structures which were trapped in the detection chamber. As the immune reaction proceeded, a large number of "hot spots" were generated by the proximity of the Au@SiO array substrate and AgNCs, greatly amplifying SERS signals. With this chip, the limits of detection of the SCCA and CEA levels in human serum were estimated to be as low as 0.45 pg mL and 0.36 pg mL, respectively. Furthermore, the good selectivity and reproducibility of this chip were confirmed. Finally, clinical serum samples were analyzed by this chip, and the outcomes were consistent with those of enzyme-linked immunosorbent assay (ELISA). Thus, the proposed microfluidic chip can be potentially applied for the clinical diagnosis of cervical cancer.
本工作开发了一种基于 Au@SiO 阵列的高活性 SERS 基底的微流控芯片,用于定量检测与宫颈癌相关的鳞状细胞癌抗原 (SCCA) 和癌胚抗原 (CEA)。该芯片由六个功能单元组成,采用无泵设计,能够自动平行检测多个样本,无需外部泵,提高了便携性。Ag 纳米立方体 (AgNCs) 被标记上拉曼报告分子,并与抗体偶联 (标记) 以制备 SERS 标签,而 Au 纳米粒子修饰的 SiO 微球 (Au@SiO) 阵列与抗体偶联 (包被) 以生成高 SERS 活性的捕获基底。在存在靶标生物标志物的情况下,它们被 SERS 标签和捕获基底捕获,形成“三明治”结构,被捕获在检测室中。随着免疫反应的进行,Au@SiO 阵列基底和 AgNCs 的接近产生了大量的“热点”,大大增强了 SERS 信号。使用该芯片,估计人血清中 SCCA 和 CEA 水平的检测限低至 0.45 pg mL 和 0.36 pg mL。此外,还证实了该芯片具有良好的选择性和重现性。最后,通过该芯片分析了临床血清样本,结果与酶联免疫吸附测定 (ELISA) 的结果一致。因此,所提出的微流控芯片可潜在应用于宫颈癌的临床诊断。